SCHEMBL5047083

SCHEMBL5047083

CN(Cc1ccc(F)cc1)c1cc(C(O)C=Cc2ccc(C(=O)O)c(O)c2)cc2c1C(C)(C)CCC2(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 5/20 0.42
RARA P10276 4/20 0.42
RARG P13631 4/20 0.42
RXRA P19793 5/20 0.34
RXRB P28702 2/20 0.33
RXRG P48443 2/20 0.33
MCL1 Q07820 2/20 0.33
PTPN1 P18031 1/20 0.32
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32
BCL2L1 Q07817 1/20 0.31
NR1H4 Q96RI1 1/20 0.31
STAT3 P40763 2/20 0.31
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30
PDK1 Q15118 1/20 0.30
PDK2 Q15119 1/20 0.30
PDK3 Q15120 1/20 0.30
PDK4 Q16654 1/20 0.30
PPARA Q07869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047077 1.00 RARB (0.42) RARBRARARARGRXRARXRB
SCHEMBL5050776 0.93 RARA (0.43) RARBRARARARGRXRARXRB
SCHEMBL5050772 0.93 RARA (0.43) RARBRARARARGRXRARXRB
SCHEMBL5047273 0.92 RARA (0.42) RARBRARARARGRXRARXRB
SCHEMBL5047269 0.92 RARA (0.42) RARBRARARARGRXRARXRB
SCHEMBL5047110 0.89 RARB (0.56) RARBRARARARGRXRARXRB
SCHEMBL5047105 0.89 RARB (0.56) RARBRARARARGRXRARXRB
SCHEMBL5049694 0.83 RARA (0.43) RARBRARARARGRXRARXRB
SCHEMBL5050811 0.83 RARA (0.43) RARBRARARARGRXRARXRB
SCHEMBL5049699 0.83 RARA (0.43) RARBRARARARGRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARB 2/4885RARA 1/4885RARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.